Arven Pharmaceuticals

Arven Pharmaceuticals is a Turkish pharmaceutical corporation headquartered in Istanbul and operating within Toksöz Group. Established as a separate legal entity in 2013, the company brought together the group’s investments in biotechnology, biosimilar medicines, and high-technology inhaler products. Its stated specialization is the development and manufacture of products that are technically difficult to reproduce, particularly biosimilars and inhalation medicines. The company’s origins extend to 2007, when Toksöz Group began investing in biotechnology and established a biotechnology division at the Sanovel facility in Silivri. That work was directed initially toward developing Turkey’s first biosimilar product. Arven later consolidated these activities under its own corporate structure and built a dedicated manufacturing site in Kırklareli. The factory began operations after receiving a manufacturing license from Turkey’s Pharmaceuticals and Medical Devices Agency in 2017. A related research and development center in Selimpaşa, Istanbul, received certification from Turkey’s Ministry of Industry in the same year. Arven’s biotechnology activities cover both microbial products and medicines produced using mammalian cell culture. Its development work includes reference-product characterization, cell-line development, analytical testing, process development, comparability studies, scale-up, stability testing, toxicology and clinical-trial material production. The Kırklareli facility includes upstream and downstream bioprocessing capabilities, controlled GMP manufacturing areas, purification systems, and aseptic syringe-filling operations. The company describes the site as Turkey’s first GMP-certified biotechnology manufacturing area. Arven’s most notable biosimilar is Fraven, a filgrastim product. Turkish authorities granted marketing approval in April 2016. The product is described as the first biosimilar developed and manufactured from cell culture through finished product entirely in Turkey. Arven also patented aspects of the product’s manufacturing protocol before the European Patent Office, supporting later work on more complex biological molecules, including monoclonal antibodies. The company’s inhaler platform is centered on Arvohaler, a multi-unit-dose dry powder inhaler designed and developed in Turkey. Development began in 2006 with domestic capital and involved Arven’s research, intellectual-property, and related technical teams working with a local mold and device manufacturer. The device and associated formulation technology have been protected through patent families in Turkey, Europe, the United States, Japan, China, and other jurisdictions. Arven introduced Cyplos, a salmeterol/fluticasone inhaled product used with the Arvohaler device, to the Turkish market in 2012 after completing the Turkish authorization process in 2011. Other products associated with the platform include Tutast Arvohaler, based on tiotropium bromide. Arven has presented itself as the first Turkish company to develop biosimilars for global markets and as the first Turkish pharmaceutical company to design and develop a patented dry powder inhaler. Its portfolio and research agenda place it at the intersection of generic pharmaceuticals, specialty medicines, device-enabled drug delivery, and biotechnology. During the COVID-19 pandemic period, Turkish health-ministry-related institutions visited the company’s facilities in connection with potential vaccine-manufacturing capabilities. Publicly available reference material does not establish that Arven subsequently commercialized a COVID-19 vaccine. As of the available reference information, Arven remains an active, privately held Turkish pharmaceutical manufacturer and research company.

Arven Pharmaceuticals developed from Toksöz Group’s long-term investment in Turkish biotechnology and pharmaceutical manufacturing. In 2007, the group began initiatives intended to advance biotechnological products and created a biotechnology division at the Sanovel facility in Silivri. Research and development began with the objective of producing a biosimilar medicine domestically, including work on cell lines, analytical methods, manufacturing processes, and comparability against reference products. The group subsequently gathered its high-technology inhaler and biotechnology activities under the separate legal entity Arven İlaç Sanayi ve Ticaret A.Ş. In 2013, Toksöz Group decided to establish a dedicated Arven factory, leading to the construction of a large manufacturing site in the Kırklareli Industrial Zone near Turkey’s western border. The factory occupies approximately 30,000 square metres and received its manufacturing license from the Turkish Pharmaceuticals and Medical Devices Agency in 2017. Arven also established an R&D facility in Selimpaşa, Istanbul, during the same period. The R&D center received certification from the Ministry of Industry in 2017 and became the company’s principal base for work on respiratory medicines and biosimilars. Arven’s biotechnology organization is divided between microbial and mammalian-cell programs. Its capabilities cover upstream operations such as inoculation, fermentation, cell disruption, and harvesting, together with downstream filtration and chromatographic purification. The company also operates controlled GMP-classified areas for bulk production and validated aseptic filling processes for finished products. This infrastructure supports the sequence of activities normally required for biosimilar development: reference-product characterization, cell-line development, analytical-method creation, process optimization, head-to-head comparability, toxicology and clinical-trial batches, stability studies, and early clinical work. The first major result of this program was Fraven, a biosimilar version of filgrastim. Turkish authorities approved the product in April 2016. Arven characterized Fraven as the first biosimilar developed and manufactured entirely within Turkey, from cell-based development through the finished medicine. The company also obtained patent protection in Europe for elements of the manufacturing protocol. This achievement provided a platform for projects involving increasingly complex biological molecules, including monoclonal antibodies. Arven’s second principal technology area is inhaled medicine. Work on the Arvohaler dry powder inhaler began in 2006, before the company’s formal establishment as a separate entity. The device was designed with domestic capital and developed by teams working across research and development, intellectual property, and related technical functions, together with a Turkish mold and device manufacturer operating clean-room facilities. The resulting device is a multi-unit-dose inhaler composed of plastic components and stainless-steel springs. Its design and related formulation technologies have been the subject of patent families in Turkey and several international jurisdictions. The first major product using this platform was Cyplos Arvohaler, combining salmeterol and fluticasone propionate. Turkish authorization was completed in 2011, and the product was launched in Turkey in 2012. Arven has described the product and device combination as a domestic Turkish development designed to comply with relevant international pharmaceutical and device expectations. The company has also associated Tutast Arvohaler, containing tiotropium bromide, with its inhaler portfolio. Arven’s manufacturing model integrates pharmaceutical formulation with device production. Medical-grade plastic parts for Arvohaler are produced in clean-room conditions, while the drug product undergoes weighing, mixing, blister filling, and assembly with the inhaler. Final operations include device assembly, labeling, and secondary packaging, followed by in-process and chemical testing. By 2020, reference material reported approximately 200 employees across the company’s factory and R&D operations. Arven had also filed hundreds of patent applications since its foundation, with a substantial share relating to Arvohaler and associated formulation technologies. During the COVID-19 period, health-ministry-related organizations visited the company to consider its potential for vaccine manufacturing. The available material does not establish that this exploration resulted in a commercial vaccine. Arven’s documented identity therefore remains that of a privately held Turkish developer and manufacturer focused on biosimilars, biotechnology, inhalation products, and proprietary drug-delivery devices.

• 2017

  Kırklareli factory and Istanbul R&D center become operational

  [1]Arven Pharmaceuticalsen.wikipedia.org

  The Kırklareli plant began licensed manufacturing, while the Selimpaşa R&D center received Ministry of Industry certification.

• 2016

  Fraven biosimilar receives marketing approval

  [1]Arven Pharmaceuticalsen.wikipedia.org

  Turkey’s Ministry of Health approved Fraven, Arven’s filgrastim biosimilar and the company’s first major biosimilar product.

• 2013

  Arven Pharmaceuticals is established as a separate company

  [1]Arven Pharmaceuticalsen.wikipedia.org

  Toksöz Group formed Arven İlaç Sanayi ve Ticaret A.Ş. to consolidate its high-technology inhaler and biotechnology activities.

• 2012

  Cyplos Arvohaler launches in Turkey

  [1]Arven Pharmaceuticalsen.wikipedia.org

  Cyplos Arvohaler entered the Turkish market as Arven’s principal inhaler-platform product.

• 2011

  Cyplos Arvohaler receives Turkish authorization

  [1]Arven Pharmaceuticalsen.wikipedia.org

  The Turkish authorization process for the salmeterol/fluticasone product used with the Arvohaler device was completed.

• 2007

  Toksöz Group starts biotechnology investment program

  [1]Arven Pharmaceuticalsen.wikipedia.org

  Toksöz Group established a biotechnology division at the Sanovel Silivri facility and initiated research intended to produce Turkey’s first biosimilar medicine.

• 2006

  Development of the Arvohaler inhaler begins

  [1]Arven Pharmaceuticalsen.wikipedia.org

  Development began on a domestically designed, multi-unit-dose dry powder inhaler and its associated formulation technology.

A Turkish specialty-pharmaceutical and biotechnology company positioned around technically complex medicines, domestic development capabilities, biosimilar manufacturing, and proprietary inhaler-device technology.

• Biosimilar medicine · 2016

  Fraven

  Fraven is Arven’s biosimilar version of filgrastim, a biotechnology medicine. Turkish authorities approved it in April 2016. Arven describes it as the first biosimilar developed and manufactured entirely in Turkey, from cell-based development through production of the finished medicine. Its development involved the company’s biotechnology research, manufacturing, quality-control, and aseptic-filling capabilities.

• Dry powder inhaler medicine · 2012

  Cyplos Arvohaler

  Cyplos Arvohaler is an inhaled combination product containing salmeterol and fluticasone propionate. It is delivered through Arven’s Arvohaler dry powder inhaler platform. The product is manufactured in several stated strength combinations, including 50/500 micrograms, 50/250 micrograms, and 50/100 micrograms. Turkish authorization was completed in 2011 and the product launched in Turkey in 2012.

• Dry powder inhaler medicine

  Tutast Arvohaler

  Tutast Arvohaler is an inhaled product associated with Arven’s proprietary dry powder inhaler platform and based on tiotropium bromide. The available reference identifies it as one of the company’s main products but does not provide a launch date, detailed market information, or current regulatory status.

• Drug-delivery device · 2012

  Arvohaler

  Arvohaler is Arven’s multi-unit-dose dry powder inhaler device. It was designed and developed in Turkey and contains 18 components, including plastic parts and stainless-steel springs. The platform is manufactured through clean-room production of medical-grade plastic components, blister filling, coiling, assembly, labeling, and packaging. Patent protection has been obtained or pursued in Turkey, Europe, the United States, Japan, China, and other markets.

• 2016

  Commercialization of the Fraven filgrastim biosimilarProduct launch

  Background

  Arven’s biotechnology program was designed to create a domestically developed biosimilar and to establish Turkish manufacturing capabilities for complex biological medicines.

  Action taken

  Following Turkish marketing authorization in April 2016, Arven commercialized Fraven as a filgrastim biosimilar.

  Aftermath

  The product became a landmark for Arven’s biotechnology business and supported the company’s move toward more complex biomolecules.

  Source

• 2013

  Creation of a dedicated Arven pharmaceutical entityStrategy

  Background

  Toksöz Group had developed biotechnology and inhaler activities through earlier group facilities and decided to bring these high-technology activities together under a dedicated company and manufacturing strategy.

  Action taken

  The group established Arven İlaç Sanayi ve Ticaret A.Ş. and proceeded with plans for a dedicated factory in Kırklareli.

  Aftermath

  The decision created the organizational and manufacturing base for Arven’s later biosimilar and inhaler programs.

  Source

• Evaluation of vaccine-manufacturing potential during the COVID-19 periodStrategy

  Background

  During the COVID-19 pandemic period, health-ministry-related organizations examined Turkish pharmaceutical manufacturing capacity and visited Arven facilities.

  Action taken

  Arven’s facilities were visited in connection with possible vaccine-manufacturing capabilities.

  Aftermath

  The available reference does not confirm that Arven developed or commercialized a COVID-19 vaccine.

  Source

• 2017

  Arven’s Kırklareli manufacturing facility begins licensed operations[1]Arven Pharmaceuticalsen.wikipedia.org

  Other · Regulation

  Arven’s dedicated Kırklareli factory began operating after obtaining a manufacturing license from Turkey’s Pharmaceuticals and Medical Devices Agency.

• 2016

  Arven receives Turkish marketing authorization for Fraven biosimilar[1]Arven Pharmaceuticalsen.wikipedia.org

  Product launch · Regulation

  Turkey’s Ministry of Health approved Fraven, Arven’s filgrastim biosimilar. The product was described as the first biosimilar developed and manufactured from cell to finished product in Turkey.

• Health authorities visit Arven facilities during the COVID-19 period[1]Arven Pharmaceuticalsen.wikipedia.org

  Other

  Foundations associated with Turkey’s Ministry of Health visited Arven facilities to examine possible vaccine-manufacturing capabilities during the COVID-19 pandemic period. The available reference does not confirm a resulting vaccine program or product.

1. 1Arven Pharmaceuticalsen.wikipedia.org